Timothy R. Barakett, a member of KKR & Co. Inc.'s board, reported an open-market purchase of 50,000 shares of common stock on March 4, 2026. The transaction carried a weighted average price of $94.47 per share and amounted to a total consideration of $4,723,500. Reported execution prices for the lots ranged from $94.29 to $94.55. After the purchase, Barakett is listed as holding 2,771 shares directly and 285,000 shares indirectly through a Limited Partnership.
The stock acquisition arrives as KKR continues to manage several corporate initiatives and respond to recent quarterly results. The firm reported adjusted earnings per share of $1.12 for the fourth quarter, below the $1.15 consensus estimate. That earnings shortfall prompted Barclays to lower its price target on KKR stock from $159 to $136, while the broker retained an Overweight rating.
Separately, KKR is reported to be exploring the sale of its information-services provider BMC Helix, with the potential transaction size cited at up to $1.5 billion. The firm is also in discussions about a possible renewable energy joint venture with South Korea's SK Group intended to consolidate renewable energy assets and project development capabilities.
KKR-backed Global Medical Response has taken steps toward a public listing, selecting banks for an initial public offering that is expected to raise about $1 billion. Meanwhile, significant insider buying activity at KKR has been noted: Co-CEOs Joseph Bae and Scott Nuttall, together with board director Mary Dillon, have purchased roughly $46 million of company stock since February.
These moves - director-level buying, executive and director purchases totaling tens of millions, an earnings shortfall that altered analyst targets, and active portfolio maneuvers including potential asset sales, a renewable-energy tie-up and an IPO for a portfolio company - outline a busy strategic period for KKR.
Context and near-term implications
The director purchase increases Barakett's direct stake modestly relative to his indirect holdings and aligns with other insider acquisitions at the firm. At the same time, the company is addressing underperformance relative to consensus and is evaluating portfolio transactions that could shift its asset mix and capital deployment plans.